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Abstract
 
Posttranslational modification of peptide antigens has been shown to alter the ability of T cells
to recognize major histocompatibility complex (MHC) class I–restricted peptides. However,
the existence and origin of naturally processed phosphorylated peptides presented by MHC
class I molecules have not been explored. By using mass spectrometry, significant numbers of
naturally processed phosphorylated peptides were detected in association with several human
 
MHC class I molecules. In addition, CD8
 
1
 
 T cells could be generated that specifically recog-
nized a phosphorylated epitope. Thus, phosphorylated peptides are part of the repertoire of an-
tigens available for recognition by T cells in vivo.
Key words: MHC class I • posttranslational protein processing • phosphopeptides • mass 
spectrometry • cytotoxic T lymphocytes
 
Introduction
 
MHC class I molecules are expressed on the surface of al-
most all nucleated cells and are responsible for the presenta-
tion of antigenic peptides to CD8
 
1
 
 CTLs. The presented
epitopes are typically generated from proteins which are
synthesized in the cytosol, degraded by proteases, and
transported into the lumen of the endoplasmic reticulum
via the transporter associated with antigen processing
 
(TAP).
 
1
 
 Then, the peptides are loaded onto newly synthe-
sized MHC class I molecules and trafficked to the cell sur-
face (1, 2). By using mass spectrometry (MS), it has been
demonstrated that as many as 10,000 different peptide spe-
cies are presented by individual class I MHC alleles. These
 
range in abundance from 1 to 
 
.
 
4,000 copies per cell (3).
The peptide sequences in these complex mixtures can also
be determined by MS (4–6). Most importantly, this tech-
nique facilitates direct identification of peptide antigens that
are associated with class I or class II MHC molecules on the
cell surface (4, 5, 7–9).
By using MS, several MHC class I–associated peptides
have been found to contain posttranslational modifications.
These modifications include deamidation of asparagine (10,
11), cysteinylation of cysteine (12–14), and glycosylation
 
(15). Posttranslational modification alters the ability of
T lymphocytes to recognize MHC class I– or class II–
restricted epitopes (10, 12–17). Recently, Hogan et al. (18)
identified the only published example of a naturally pro-
cessed and presented phosphorylated peptide associated
with any MHC molecule. However, the ability of this
phosphorylated peptide to be recognized by T lymphocytes
was not investigated. More recently, Andersen et al. (19)
demonstrated that synthetic phosphorylated MHC class I
peptide epitopes can be transported by TAP, can bind to
MHC class I molecules, and can be recognized by specific
CTLs. Since the complexity and origin of phosphorylated
peptides presented by MHC molecules are unknown, we
have used MS to explore this issue. We have also evaluated
the ability of these naturally processed phosphorylated pep-
tides to stimulate specific immune responses.
 
Materials and Methods
 
Cell Lines and Transfectants.
 
All cell lines were grown in
growth medium consisting of RPMI 1640 supplemented with 5%
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Abbreviations used in this paper:
 
 B-LCL, B lymphoblastoid cell line;
c.eq., cell equivalents; DC, dendritic cell; ESI, electrospray ionization;
IMAC, immobilized metal ion affinity chromatography; ID, inner diame-
ter; MARCKS, myristoylated Ala-rich protein kinase C substrate; MS,
mass spectrometry; OD, outer diameter; TAP, transporter associated with
antigen processing. 
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FCS with SerXtend (Irvine Scientific). JY (HLA-A
 
*
 
0201,
-A
 
*
 
0201, -B7, -B7, -DR4, -DR6), ABB (HLA-A2, -A3, -B7,
-B35, -DR
 
*
 
01, -DR103), and Ruppen (HLA-A1, -A2, -B8,
–B27) are all EBV-transformed B lymphoblastoid cell lines (B-
LCLs). VBT2 (HLA-A34, -A
 
*
 
6802, -B35, -Cw4) is a squamous
lung carcinoma that has been described previously (18, 20). T2-
B7 is an HLA-A
 
*
 
0201
 
1
 
 human B-LCL with a deletion in the
MHC including the genes for TAP1, TAP2, LMP2, and LMP7
(21, 22) which has been transfected with HLA-B
 
*
 
0702. T2-B7
was grown under selection in growth medium supplemented with
300 
 
m
 
g/ml hygromycin B. A transfectant of the B-LCL C1R ex-
pressing chimeric MHC class I molecule consisting of 
 
a
 
1 and 
 
a
 
2
domains of HLA-A
 
*
 
0201 and 
 
a
 
3 domain of H-2
 
D
 
 (AAD) has
been described previously (23, 24), and was maintained under se-
lection in growth medium supplemented with 300 
 
m
 
g/ml G418.
 
Isolation of HLA-associated Peptides.
 
MHC class I molecules
were immunoaffinity purified from B-LCLs, and their associated
peptides were extracted as described previously (5, 22) with slight
modifications. Between 5
 
 3 
 
10
 
8
 
 and 2
 
 3 
 
10
 
9
 
 cells were lysed in
20 mM Tris-HCl, pH 8.0, 150 mM NaCl with 1% 3-[(3-chola-
midopropyl) dimethylammonio]-1-propane sulfonate (CHAPS),
1 mM PMSF, 5 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml
pepstatin A, and 1:100 dilutions of phosphatase inhibitor cocktails
I and II (Sigma-Aldrich), in order to prevent potential dephos-
phorylation of peptides during extraction. After sample centrifu-
gation, supernatants were incubated with Abs specific for MHC
class I molecules (Ab GAP-A3 specific for HLA-A3; BB7.2 spe-
cific for HLA-A2.1 [25]; ME1-1.2 specific for HLA-B7 and
-B27; W6/32 specific for HLA-A, -B, and -C [26]; or B1.23.2
specific for HLA-B and -C [27]) that had been bound to recom-
binant protein A–Sepharose fast-flow (Amersham Pharmacia Bio-
tech). Purification of multiple MHC class I alleles from a single
cell line was accomplished by sequential immunoaffinity purifica-
tion. Peptides were eluted from the MHC class I molecules with
10% acetic acid and separated into Teflon eppendorf tubes
(Savillex) using a 5,000-dalton cutoff ULTRAFREE-MC filter
(Millipore). Extracts were stored at 
 
2
 
80
 
8
 
C.
 
Immobilized Metal Affinity Chromatography Enrichment of Phos-
phorylated Peptides.
 
Immobilized metal affinity chromatography
(IMAC) columns were constructed by packing 360 
 
m
 
m outer
diameter (OD) 
 
3
 
 100 
 
m
 
m
 
 
 
inner diameter (ID) fused silica
(Polymicro Technologies) with 8 cm POROS 20 MC (PerSep-
tive Biosystems). Columns were activated with 200 
 
m
 
l of 100
mM FeCl
 
3
 
 (Sigma-Aldrich). Between 1.5 
 
3
 
 10
 
8
 
 and 1.4 
 
3
 
 10
 
9
 
cell equivalents (c.eq.) of HLA-extracted peptide in 10% acetic
acid (Sigma-Aldrich) were loaded onto the column in each ex-
periment. To remove nonspecific binding peptides, the column
was washed with a solution of 100 mM NaCl (Sigma-Aldrich) in
acetonitrile (Mallinkrodt), water, and glacial acetic acid (25:74:1
[vol/vol/vol]; Sigma-Aldrich). This column was then connected
to a second fused silica column packed with 6 cm of 5–20 
 
m
 
m
C18 (YMC) via 1 cm of 0.012-in ID 
 
3
 
 0.060-in
 
 
 
OD Teflon
tubing (Zeus). Phosphorylated peptides were eluted to the pre-
column with 5 
 
m
 
l of 50 mM Na
 
2
 
HPO
 
4
 
 (pH 9.0; Sigma-Aldrich)
and rinsed with several column volumes of 0.1% acetic acid to re-
move salts before MS analysis.
 
Liquid Chromatography/MS/MS Parameters on the LCQ Ion Trap
Mass Spectrometer.
 
IMAC-enriched phosphorylated peptides
were analyzed by a procedure described previously (28) using
nanoflow-HPLC/microelectrospray ionization (
 
m
 
ESI)/MS/MS
on an LCQ ion trap mass spectrometer (Finnigan). In brief, pre-
columns were connected via 0.012-in ID 
 
3
 
 0.060-in OD Teflon
tubing to an analytical column with a laser-pulled ESI emitter tip
 
(2–4 
 
m
 
m in diameter). Peptides were eluted into the mass spec-
trometer with an HPLC (model 140B; Applied Biosystems) gra-
dient (consisting of 5–60% B in 40 min; A 
 
5 
 
aqueous 0.1 M ace-
tic acid, B 
 
5 
 
70% acetonitrile with 0.1 M acetic acid). The mass
spectrometer was operated in data-dependent mode and cycled
through a single MS and five MS/MS experiments every 12–15 s.
MS/MS experiments (collision energy 40%) were performed on
the five most abundant ions (3-dalton window; precursor 
 
m/z
 
 
 
6
 
1.5 daltons) in each full-scan mass spectrum.
 
Identification and Sequencing of Phosphopeptide MS/MS Spectra.
 
Spectra of candidate phosphopeptides were selected from the
800–1,000 MS/MS spectra acquired during a typical
 
 
 
HPLC-MS/
MS experiment with an in-house computer algorithm termed the
Neutral Loss Tool. This program screens MS/MS spectra for sig-
nals at 
 
m/z
 
 values corresponding to the loss of phosphoric acid 49
or 98 daltons from doubly or singly charged precursor ions, re-
spectively. This process is commonly observed in ion trap MS/
MS spectra of phosphorylated peptides (29). Candidate peptides
were sequenced de novo and with the aid of the database search-
ing program MS-Tag (available at http://prospector.ucsf.edu/
ucsfhtml3.4/mstagfd.htm).
 
Negative Ion Precursor Parameters on the TSQ-7000 Triple Qua-
drupole Mass Spectrometer.
 
Phosphorylated peptides were also an-
alyzed on a Finnigan TSQ-7000 triple quadrupole mass spec-
trometer operating in the negative ion mode (spray voltage, 
 
2
 
1.6
kV). The nanoflow HPLC-
 
m
 
ESI setup, column assembly, and
HPLC gradient conditions were the same as above. The mass
spectrometer was set to perform precursor scans with Q1 scan-
ning 
 
m/z
 
 400 – 
 
m/z
 
 800 and Q3 set to transmit ions of 
 
m/z
 
 79.
Q1 and Q3 were operated with resolutions of 2 and 1 daltons,
respectively. Q2 was operated with a collision cell offset of 40 V
and an argon pressure of 3 mTorr.
 
Peptide Synthesis.
 
Peptides were synthesized as described (12).
9-fluorenylmethoxycarbonyl (Fmoc)-protected amino acids,
phosphorylated amino acids, and resins were purchased from
Novabiochem. Peptides were purified by reversed-phase
 
 
 
HPLC
and sequences were confirmed by MS/MS experiments.
 
Generation of Phosphopeptide-specific CTLs.
 
C57Bl/6 mice
transgenic for the AAD gene have been described previously (30).
Dendritic cells (DCs) were generated as described previously (31)
with some modifications. On day 7, DCs were isolated using a
StemSep column after incubation of GM-CSF/IL-4–cultured
bone marrow–derived cells with a mixture of Abs for the enrich-
ment of DCs (StemCell Technologies Inc.). Enriched DCs were
then incubated with CD40L-transfected NIH-3T3 cells (a gift of
Dr. Rejean Lapointe, National Cancer Institute, Bethesda, MD)
for 14–16 h. CD40-activated “mature” DCs were pulsed with 1
 
m
 
M phosphorylated peptide for 4 h at 37
 
8
 
C in HBSS containing
5% FCS, washed twice, and resuspended in saline at 10
 
6
 
 cells/ml.
Mice were injected in the tail vein with 10
 
5
 
 DCs in 100 
 
m
 
l.
Spleens from primed mice were harvested 3 wk after immuni-
zation. Separate bulk T cell cultures were established in vitro
with irradiated splenocytes that had been pulsed with 10, 1, or
0.1 
 
m
 
M phosphorylated peptide as described previously (31).
Cultures were restimulated with irradiated, peptide-pulsed autol-
ogous splenocytes every 7–10 d. All CTL lines were grown in
CTL medium (consisting of RPMI 1640 supplemented with 10%
FCS, 2 mM 
 
L
 
-glutamine, essential and nonessential amino acids,
50 
 
m
 
M 
 
b
 
-mercaptoethanol, 15 mM Hepes, and gentamicin) and
10 U/ml of IL-2 in a humidified 8% CO
 
2
 
 atmosphere at 37
 
8
 
C.
 
Analysis of In Vitro Cytotoxicity and Intracellular Cytokine Produc-
tion.
 
Standard 
 
51
 
Cr-release assays were performed to determine
CTL recognition of phosphorylated or nonphosphorylated pep- 
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tides. Target cells were labeled overnight with 
 
51
 
Cr, pulsed with
phosphorylated or nonphosphorylated peptides for 45 min,
washed, and incubated with effector cells (at E/T ratios indicated
in Fig. 2) for 4 h at 37
 
8
 
C. The evaluation of intracellular cytokine
production was completed as described previously (31, 32).
 
HLA-A
 
*
 
0201 Peptide-binding Assay.
 
The relative affinities of
phosphorylated peptides to bind to HLA-A
 
*
 
0201 were measured
as described previously (33), and the dose of individual peptides
that reduced the binding of the indicator peptide by 50% (IC
 
50
 
)
was determined.
 
Results
 
We have evaluated the repertoire of naturally processed
and presented phosphorylated peptides presented by MHC
class I molecules isolated from several different EBV-trans-
formed B-LCLs. Detection of phosphorylated species in
the pool of 
 
.
 
10,000 class I MHC–binding peptides was fa-
cilitated by selective enrichment using IMAC (34, 35). The
presence of phosphorylated peptides in the resulting en-
riched sample was confirmed by screening MS/MS spectra
of individual peptide ions for an abundant loss of phospho-
ric acid from the precursor mass. This neutral loss is a com-
mon feature in ion trap MS/MS spectra of phosphoserine
(pSer) and phosphothreonine (pThr) containing peptides,
but not those containing phosphotyrosine (pTyr). When
1.5 
 
3
 
 10
 
8
 
 c.eq. of peptides extracted from HLA-B7 were
analyzed by this method, 60 phosphorylated peptides were
detected (Table I). Thus, phosphorylated peptides are a sig-
nificant part of the repertoire of antigens presented by this
MHC class I molecule for recognition by CD8
 
1
 
 T lym-
phocytes.
To confirm the generality of this observation, we ana-
lyzed peptides eluted from several additional human MHC
class I alleles including: HLA-A1, -A
 
*
 
0201, -A3, -A
 
*
 
6802,
-B8, -B27, and HLA-B35. Naturally processed phosphory-
lated peptides were found to be associated with all of these
MHC class I molecules (Table I). Interestingly, many of the
HLA-B alleles examined present a larger number of phos-
phorylated peptides (43–60 peptides) than do any of the
HLA-A alleles analyzed (9–15 peptides [Table I]). This dis-
parity could be due to significant differences in overall ion-
ization efficiency, reflecting the fact that the binding motif
for many of the HLA-B alleles includes positively charged
residues, whereas those for the HLA-A alleles do not. To
eliminate this possibility, we also determined the number
of phosphorylated peptides in HLA-A2 and HLA-B7 ex-
tracts by negative ion MS using precursor scans (36, 37). In
this approach, MS/MS spectra of negatively charged phos-
phopeptide ions were screened for the presence of a diag-
nostic fragment mass corresponding to PO
 
3
 
2
 
 (
 
m/z
 
 79 [36,
37]). When the HLA-B7 extract was analyzed by this tech-
nique, 122 phosphopeptides were detected (Table I). Only
21 phosphopeptides were detected in the HLA-A
 
*
 
0201 ex-
tract (Table I). Thus, the relative number of phosphopep-
tides observed in these two extracts is not a function of the
ionization method used to detect them. We suggest that
the differences in numbers of phosphopeptides presented
by HLA-A and -B alleles are likely to reflect common
structural features of MHC binding and phosphokinase
recognition motifs.
To investigate the pathway by which phosphorylated
MHC class I–associated peptides are presented, we ana-
lyzed peptides eluted from HLA-A2 and HLA-B7 mole-
cules expressed in a cell line that is deficient for TAP ex-
pression (T2-B7). We did not detect any phosphorylated
peptides associated with either HLA-A2 or HLA-B7 in the
TAP-deficient cell line (Table I). However, nonphosphor-
ylated peptides were present in these extracts (data not
shown). These have been shown previously to originate
from proteolysis of peptides within the lumen of the endo-
plasmic reticulum (22, 38). The absence of phosphorylated
peptides from these extracts demonstrates that their presen-
tation is strictly TAP dependent. This in turn suggests that
the major source of these peptides is proteins that are pro-
cessed in the cytosol.
15 phosphorylated peptides in the IMAC-enriched
MHC class I extracts were sequenced on the ion trap mass
spectrometer. An example is shown in Fig. 1. These se-
quences were confirmed by comparing the observed spec-
tra with those of the corresponding synthetic peptides. 13
of these phosphorylated peptides contained pSer, whereas
only two contained pThr and none contained pTyr (Table
 
Table I.
 
Enumeration of Phosphorylated Peptides Associated with 
MHC Class I Molecules
 
Number of phosphorylated
peptide candidates
Cell line
MHC
class I allele
Positive ion
analysis
 
*
 
Negative ion
analysis
 
‡
 
3 
 
3
 
 10
 
8
 
 c.eq. 5 3 108 c.eq.
Ruppen HLA-A1 15 –
JY HLA-A*0201 11§ 21
T2-B7 HLA-A*0201 0i –
ABB HLA-A3 12 –
VBT2 HLA-A*6802 9 –
JY HLA-B7 60§ 122
T2-B7 HLA-B7 0i –
Ruppen HLA-B8 43 –
Ruppen HLA-B27 45 –
ABB HLA-B35 26 –
*Enumeration of phosphorylated peptides was completed using the
Neutral Loss Tool as described in Materials and Methods.
‡The number of phosphorylated peptides was determined by enumer-
ating ion species that lost m/z of 79 in negative ion mode as described
in Materials and Methods.
§For the HLA-A2.1 and HLA-B7 extracts, 1.5 3 108 c.eq. was utilized
in order to account for the homozygosity of the alleles in the JY cell line.
iDue to the level of HLA-A2 and HLA-B7 found on the cell surface of
T2-B7, 4.5 3 108 c.eq. was loaded for HLA-A2 and 1.3 3 109 c.eq.
for HLA-B7.1758 Identification of Phosphorylated MHC Peptides
II). This finding is in accord with the relative levels of these
phospho-amino acids in the cell (39). 13 of these peptides
contained only a single phosphorylated residue, even
though many contained additional Ser, Thr, or Tyr resi-
dues. One peptide identified in the HLA-B27 extract
(RRFpSRpSPIRR) contained two pSer residues (Table
II). Interestingly, this extract also contained a truncated
version of this peptide (RRFpSRpSPIR), as well as a singly
phosphorylated variant (RRFpSRSPIRR [Table II]).
Finally, an Arg or Lys residue is found 3–4 amino acids
NH2-terminal to the phosphorylated residue in 13 of these
peptides, and a Pro residue is found 2–3 amino acids NH2-
terminal of the phosphorylated residue in 5 of these pep-
tides. These findings suggest that phosphorylation of these
peptides is sequence specific and are consistent with the
motif requirements for Ser-Thr kinase recognition.
All sequences in Table II (with the exception of the
RRFpSRpSPIRR epitope) matched to unique source pro-
teins in the nonredundant and OWL (available at http://
prospector.ucsf.edu/ucsfhtml3.4/mstagfd.htm) protein da-
tabases. Three of the source proteins are known protein ki-
nases, two (insulin receptor substrate 2 and myristoylated
Ala-rich protein kinase C substrate  [MARCKS]) are
known kinase substrates, and two others are known phos-
phoproteins (MADS box transcription enhancer factor and
MHC-binding protein 2). However, only the HLA-B27–
restricted peptide derived from the MARCKS protein con-
tains a previously identified phosphorylation site (40). Two
of the source proteins (MUM2 and MHC class III protein
g18.1b) have not been previously shown to be phosphory-
lated, and their functions are unknown. These sequences
illustrate the diversity of phosphorylated cellular proteins
that are processed and presented by MHC class I molecules,
and illustrate the power of MS to identify new members of
phosphorylation cascades.
We used an HLA-A*0201–restricted phosphorylated
peptide derived from the MUM2 protein with the se-
Figure 1. MS/MS spectrum of the HLA-A*0201–associated peptide
RLDpSYVRSL. Predicted masses for the ions of type b and y are shown
above and below the sequence, respectively. Those observed are under-
lined. n, loss of phosphoric acid from the corresponding ion of type b or y.
Table II. Sequences of Identified Phosphorylated Peptides
Allele Peptide sequence Parent protein due to database sequence match
HLA-A*0201 RLDpSYVRSL MUM2
HLA-A*6802 RVApSPTSGV Insulin receptor substrate 2
HLA-B7 KPRpSPVVEL b-Adrenergic receptor kinase 1
GPRSASLLpSL MHC class III protein g18.1b
RPApSAGAML MADS box transcription enhancer factor 2
RPVpSPGKDI MHC binding protein 2
RPSpTPKSDSEL Hypothetical protein kiaa0188
RPAKpSMDSL Hypothetical protein kiaa1204
HLA-B8 MPHEKHYpTL Hypothetical serine/threonine kinase
HLA-B27 KRFpSFKKSF MARCKS
SRWpSGSHQF RAF homologue
RRIpSGVDRY NADH-ubiquinone oxidoreductase subunit MWFE
RRFpSRpSPIRR Son3, DNA-binding protein 5, and BASS1
RRFpSRpSPIR (Truncated version of above epitope)
RRFpSRSPIRR (Singly phosphorylated version)
BASS1, Bass antagonists selected in saccharomyces 1.1759 Zarling et al.
quence RLDpSYVRSL as a model to assess whether this
posttranslational modification could be recognized by the
immune system. AAD transgenic mice were primed intra-
venously with phosphopeptide-pulsed DCs, and the splenic
T cell effector function was assessed after restimulation
with the same peptide in vitro. Phosphopeptide-specific
cell division and growth in a population of CD81 T cells in
these cultures were detected (data not shown). However,
in three independent experiments, we could not detect
specific cytolytic activity or IFN-g production in response
to either the phosphorylated or unphosphorylated forms
of this peptide (Fig. 2 A, and data not shown). Therefore,
we also evaluated responses induced by a homolo-
gous  MUM2-derived peptide with the sequence
GLDpSYVRSL. This peptide contains an R to G muta-
tion, at position 1, previously identified by Chiari et al. (41)
as a tumor antigen. CD81 T cells from mice primed and
cultured in vitro with GLDpSYVRSL produced IFN-g af-
ter a 5-h incubation with phosphopeptide-pulsed cells (Fig.
2 A). They also killed targets pulsed with this same peptide
(Fig. 2 B). These CD81 CTLs were specific for the phos-
phopeptide and did not recognize targets pulsed with the
nonphosphorylated GLDSYVRSL (Fig. 2 B). These find-
ings established that phosphorylated peptides can stimulate
specific CTL responses after in vivo immunization and in
vitro culture.
To further evaluate the specificity of these CTLs, we
tested their ability to recognize target cells pulsed with
other phosphorylated peptides. Importantly, the CTLs elic-
ited with the GLDpSYVRSL peptide from the mutated
form of MUM2 cross-recognized the phosphorylated pep-
tide, RLDpSYVRSL, derived from wild-type MUM2
(Fig. 2, A and B). As expected, they failed to recognize the
unphosphorylated form of this peptide (data not shown).
In addition, as shown in Fig. 2, the CTLs elicited
with  GLDpSYVRSL did not recognize targets pulsed with
a distinct HLA-A2.1–binding phosphopeptide (RVA
pSPTSGV). Because this peptide also contains pSer at posi-
tion 4, this result indicates that the CTLs not only recog-
nized the pSer, but also the specific peptide context of this
residue. Finally, we evaluated the effect of substituting
pThr or pTyr for pSer in the GLDpSYVRSL sequence.
We found that the CTLs recognized the pThr and pSer
containing peptides similarly, whereas they failed to recog-
nize the pTyr peptide at any concentration tested (Fig. 2
B). Though the pTyr substitution diminished binding to
HLA-A*0201 by approximately fourfold relative to the
other two (Table III), this does not account for the differ-
ence in CTL recognition. Thus, CTLs elicited with a
phosphopeptide strongly discriminate between phosphory-
lated and nonphosphorylated peptides. However, these
CTLs are not simply phosphate specific; they also discrimi-
nate the context of the phosphate within a specific peptide
sequence.
Discussion
The phosphorylation of cellular proteins in transformed
cells is increased compared with normal cells (42, 43) and
offers an attractive target for immunotherapeutic interven-
tion. Consequently, we have investigated whether phos-
phorylated peptides are presented on the cell surface by
MHC molecules for recognition by T lymphocytes. Natu-
rally processed phosphorylated peptides were presented by
Table III. Relative Binding Affinities of MUM2-derived Peptides 
for HLA-A*0201
Sequence IC50
nM
RLDpSYVRSL 78
GLDpSYVRSL 58
GLDpYYVRSL 211
GLDpTYVRSL 67
Figure 2. Discrimination of phosphorylated peptides by CD81 T lym-
phocytes. (A) IFN-g production by phosphopeptide-specific CD81 T
cells. CD81 T cells (generated by long-term culture with the indicated
peptides as described in Materials and Methods) were stimulated for 5 h
with CIR-AAD that had been pulsed with 25 mM of one of the indicated
phosphorylated peptides and then assayed for the intracellular accumula-
tion of IFN-g. Nonspecific IFN-g accumulation was determined by the
stimulation of CD81 T cells with unpulsed CIR-AAD and was ,100/
105 CD81 T cells. (B) Specificity of GLDpSYVRSL-specific CTLs.
CD81 T cells elicited by stimulation with 1 mM GLDpSYVRSL were
analyzed for cytolytic activity using 51Cr-labeled CIR-AAD targets (E/T
ratio of 3:1) that had been pulsed with the indicated concentrations of
phosphorylated GLDpSYVRSL, RLDpSYVRSL, GLDpYYVRSL, and
GLDpTYVRSL, or nonphosphorylated GLDSYVRSL. Specific lysis of
unpulsed CIR-AAD targets was ,2%.1760 Identification of Phosphorylated MHC Peptides
all MHC class I alleles evaluated in this study, including
HLA-A1, -A*0201, -A3, -A*6802, -B7, -B8, -B27, and
HLA-B35. The presence of phosphorylated peptides in ex-
tracts from these molecules was established by their binding
to a phosphate-specific metal ion affinity column and the
loss of either H3PO4 or PO3
2 during MS/MS (29, 36, 37).
De novo sequencing confirmed that these species were
phosphorylated peptides.
A comparison of the number of phosphorylated species
demonstrated that the HLA-B alleles evaluated presented a
greater number of phosphorylated peptides than did the
HLA-A alleles. We hypothesize that this is due to the en-
hanced presentation of phosphorylated peptides by class I
MHC molecules whose binding motifs consist of amino
acids that are also components of kinase motifs. In particu-
lar, the consensus binding motifs for HLA-B7, -B8, and
–B27 contained Arg or Lys at positions 1, 2, or 3, while
motifs for HLA-B7 and HLA-B35 contain Pro at position
2 (3, 44, 45). Several kinases phosphorylate Ser or Thr resi-
dues that are three to four amino acids COOH terminal of
an Arg or Lys, or two to three amino acids COOH termi-
nal of a Pro (46). Thus, it would be expected that these
HLA-B alleles could present peptides that are phosphory-
lated at positions 4–7. Of the 12 complete and 4 partial
peptide sequences obtained from HLA-B7 and –B27 alleles,
14 are phosphorylated at position 4 and have an Arg or Lys
at position 1 or 2. Similarly, of the six peptides associated
with HLA-B7, all but one are phosphorylated two to three
amino acids COOH terminal from the Pro at position 2. It
is interesting that HLA-B7, which contains both an Arg
and Pro within its binding motif, displays a larger number
of phosphorylated peptides than the other HLA-B alleles
analyzed. In contrast, the HLA-A alleles we have analyzed
do not require an Arg, Lys, or Pro within their consensus
binding motif. This does not preclude presentation of
phosphorylated peptides containing kinase motifs: the two
phosphopeptide sequences determined for HLA-A*0201
and -A*6802 also contain an Arg at position 1 and a pSer at
position 4. However, the presentation of peptides contain-
ing consensus kinase motifs will not be selected for, as it is
the case for many HLA-B alleles.
In this study, we also evaluated whether MHC class II
molecules presented phosphorylated peptides, and failed to
detect any phosphorylated peptides in extracts from two
different B-LCLs that expressed four different HLA-DR
alleles (data not shown). It remains to be determined
whether this deficiency extends to HLA-DQ and -DP.
However, this result suggests that phosphorylated protein
segments are not generated or do not persist in the en-
docytic environment from which the processed peptides
displayed by class II MHC molecules originate. In contrast,
the pSer and pThr containing phosphopeptides displayed
by class I MHC molecules appear to be processed via the
classical class I antigen-presentation pathway involving the
TAP protein. The involvement of TAP demonstrates that
the main source of these peptides is phosphorylated pro-
teins that are processed in the cytosol, although our studies
do not address the proteases responsible. Our results extend
those of Anderson et al. (19), whose study demonstrated
that synthetic peptides containing pSer could be trans-
ported by TAP.
Several lines of evidence suggest that the phosphopep-
tides displayed by class I MHC molecules are the products
of normal protein phosphorylation pathways in cells rather
than adventitious or artifactual phosphorylation of the pep-
tides themselves. As previously mentioned, most of the
phosphopeptide sequences determined are consistent with
known Ser-Thr kinase motifs, and these peptides originate
from the cytosol, where the majority of such kinases are
expected to operate. In addition, the relative representation
of pSer, pThr, and pTyr among these sequences is consis-
tent with the relative quantities of these phospho-amino
acids in cells (39). In particular, pTyr represents only 0.1%
of the phospho-amino acid content of the cell, and there-
fore may not make a significant contribution to the number
of the phosphopeptides on the cell surface associated with
MHC class I molecules. Finally, many of the sequences we
have identified are from known phosphoproteins, kinases,
or kinase substrates. Whereas the exact phosphorylation
sites on most of these proteins have not been previously
determined, a peptide derived from the MARCKS protein
did contain a known site (40). Importantly, the identifica-
tion of MHC-presented phosphopeptides can provide in-
sight into known phosphorylation pathways and also offers
the possibility to identify new ones.
In this study, we demonstrated that phosphopeptides
could be used to elicit CTLs, and that these cells could dis-
criminate between phosphorylated and nonphosphorylated
peptides. Similar findings have been reported by Andersen
et al. (19). Here we have also shown that the CTLs elicited
with the GLDpSYVRSL peptide failed to recognize other
peptides that carried a pSer at position 4. These CTLs
could also discriminate between different phosphorylated
amino acids even when they were presented within the
same peptide context. Thus, these CTLs are not phosphate
specific, but rather recognize this moiety in the context of a
specific peptide sequence. It should be noted that the abil-
ity to generate phosphopeptide-specific CTLs indicates that
phosphopeptides presented by MHC molecules are pro-
tected from the action of phosphatases both in vivo and in
vitro. This augers well for the use of such peptides both as
vaccines and to develop T cell reagents for use in adoptive
immunotherapy.
The identification of peptide epitopes expressed on tu-
mors has led to the development of novel vaccines for can-
cer immunotherapy (47). However, the number of identi-
fied targets is still small, and these tumor antigens are often
expressed on normal cells and on the tumors (48, 49). Be-
cause proteins from cancer cells have been shown to be dif-
ferentially phosphorylated in contrast to normal cellular
proteins due to increased deregulation of phosphorylation
(43, 50), we are isolating phosphorylated peptides found on
different carcinoma cell lines to identify tumor-specific an-
tigens. Identification of these phosphorylated epitopes will
provide a new set of tumor-specific antigens for use in im-
munotherapy.1761 Zarling et al.
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